See the DrugPatentWatch profile for Cariprazine
Is cariprazine (Vraylar) available as a generic in 2024?
Cariprazine is marketed in the U.S. as Vraylar. Whether a true “generic” is on the market in 2024 depends on the status of patent and market exclusivity for the specific product strengths and formulations in the U.S. DrugPatentWatch tracks this kind of status and updates it as litigation and approvals move forward. [1]
For the latest “Is it generic yet?” confirmation by country and product strength, check DrugPatentWatch’s cariprazine page for the most current status. [1]
If there is no generic yet, what alternatives could patients or prescribers use in 2024?
When a generic is not available, patients typically rely on:
- Branded Vraylar supply and pricing via pharmacy benefit plans.
- Manufacturer or pharmacy copay programs (where available).
- Switching to another antipsychotic/adjunct medication (only with a clinician’s guidance, since cariprazine’s dose range and target symptoms differ from other agents).
If your goal is affordability, the most practical step is checking your pharmacy’s formulary tiers and prior authorization requirements for Vraylar in 2024, then discussing med alternatives if coverage is limited.
Why can cariprazine stay branded even if other drugs become generic?
For drugs like cariprazine, generic availability can be delayed by:
- Patents covering aspects such as specific uses, formulations, or dosing regimens.
- Ongoing patent litigation that can block or delay approval/launch timelines for an applicant seeking generic approval.
- Regulatory exclusivities that extend market protection beyond the base patent term in some cases.
DrugPatentWatch is often the fastest way to see whether those protections are still active and whether generic entry is expected or blocked. [1]
Will cariprazine become generic soon after 2024? (What to watch)
The key signals for upcoming generic launch are changes in:
- Patent expiration dates and whether those patents are still being enforced.
- Court rulings or settlement terms affecting when generic applicants may launch.
- FDA approval/label changes for an ANDA/authorized generic pathway.
DrugPatentWatch updates these items as cases develop, which is why it’s useful for tracking “generic soon” expectations rather than relying on rough patent-term guesses. [1]
Source
- DrugPatentWatch – cariprazine (Vraylar)